Aethlon medical announces financial results for the fiscal first quarter ended june 30, 2025, and provides corporate update

Australian cancer trial advances with first cohort complete, amended protocol, and promising preclinical data published; operating expenses cut by 32% conference call to be held today at 4:30 p.m. et san diego , aug. 13, 2025 /prnewswire/ -- aethlon medical, inc. (the company or aethlon) (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended june 30, 2025, and provided an update on recent developments.
AEMD Ratings Summary
AEMD Quant Ranking